European Respiratory Society (ERS) - 20th Annual Congress.
The European Respiratory Society Congress, held in Barcelona, included topics covering new therapeutic developments in the field of respiratory health and disease. This conference report highlights selected presentations on therapies targeting inflammatory cells, with a focus on therapeutic agents for asthma and COPD. This report also includes a discussion of novel therapeutic agents for pulmonary hypertension. Investigational drugs discussed include OC-000459 (Oxagen), SCH-527123 (Merck & Co), AZD-9668 (AstraZeneca), benralizumab (MedImmune/Kyowa Hakko Kirin/BioWa), PF-3429281 (Pfizer), vilanterol (GlaxoSmithKline/Theravance), LAS-100977 (Almirall Prodesfarma), selexipag (Nippon Shinyaku/Actelion) and GW-0742 (GlaxoSmithKline).
University of Sydney, Broadway, Sydney, NSW 2006, Australia. jpseale@med.usyd.edu.au
John Paul
JP
Seale
D000818:Animals; D001249:Asthma / Q000188:drug therapy / Q000503:physiopathology; D016503:Drug Delivery Systems; D015195:Drug Design; D015507:Drugs, Investigational / Q000494:pharmacology; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy / Q000503:physiopathology; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy / Q000503:physiopathology; D012140:Respiratory Tract Diseases / Q000188:drug therapy* / Q000503:physiopathology
D015507:Drugs, Investigational